249 related articles for article (PubMed ID: 22575167)
21. A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice.
Tarcha EJ; Basrur V; Hung CY; Gardner MJ; Cole GT
Infect Immun; 2006 Jan; 74(1):516-27. PubMed ID: 16369008
[TBL] [Abstract][Full Text] [Related]
22. Rational Design of T Lymphocyte Epitope-Based Vaccines Against Coccidioides Infection.
Hurtgen BJ; Hung CY
Methods Mol Biol; 2017; 1625():45-64. PubMed ID: 28584982
[TBL] [Abstract][Full Text] [Related]
23. Th1-type immune response to a Coccidioides immitis antigen delivered by an attenuated strain of the non-invasive enteropathogen Vibrio cholerae.
Silva AJ; Benitez JA
FEMS Immunol Med Microbiol; 2005 Mar; 43(3):393-8. PubMed ID: 15708313
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.
Morgan EL; Morgan BN; Stein EA; Vitrs EL; Thoman ML; Sanderson SD; Phillips JA
Vaccine; 2009 Dec; 28(2):463-9. PubMed ID: 19836478
[TBL] [Abstract][Full Text] [Related]
25. Dectin-1 is required for resistance to coccidioidomycosis in mice.
Viriyakosol S; Jimenez Mdel P; Gurney MA; Ashbaugh ME; Fierer J
mBio; 2013 Feb; 4(1):e00597-12. PubMed ID: 23386437
[TBL] [Abstract][Full Text] [Related]
26. Molecular and cellular mechanisms of protective immunity to coccidioidomycosis.
Kirkland TN; Raz E; Datta SK
Vaccine; 2006 Jan; 24(4):495-500. PubMed ID: 16181709
[TBL] [Abstract][Full Text] [Related]
27. A recombinant beta-1,3-glucanosyltransferase homolog of Coccidioides posadasii protects mice against coccidioidomycosis.
Delgado N; Xue J; Yu JJ; Hung CY; Cole GT
Infect Immun; 2003 Jun; 71(6):3010-9. PubMed ID: 12761077
[TBL] [Abstract][Full Text] [Related]
28. Absence of phagocyte NADPH oxidase 2 leads to severe inflammatory response in lungs of mice infected with Coccidioides.
Gonzalez A; Hung CY; Cole GT
Microb Pathog; 2011 Dec; 51(6):432-41. PubMed ID: 21896326
[TBL] [Abstract][Full Text] [Related]
29. C-type lectin receptors differentially induce th17 cells and vaccine immunity to the endemic mycosis of North America.
Wang H; LeBert V; Hung CY; Galles K; Saijo S; Lin X; Cole GT; Klein BS; Wüthrich M
J Immunol; 2014 Feb; 192(3):1107-1119. PubMed ID: 24391211
[TBL] [Abstract][Full Text] [Related]
30. Co-delivery of amphipol-conjugated adjuvant with antigen, and adjuvant combinations, enhance immune protection elicited by a membrane protein-based vaccine against a mucosal challenge with Chlamydia.
Tifrea DF; Pal S; Le Bon C; Giusti F; Popot JL; Cocco MJ; Zoonens M; de la Maza LM
Vaccine; 2018 Oct; 36(45):6640-6649. PubMed ID: 30293763
[TBL] [Abstract][Full Text] [Related]
31. Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.
Karuturi BV; Tallapaka SB; Phillips JA; Sanderson SD; Vetro JA
Clin Immunol; 2015 Dec; 161(2):251-9. PubMed ID: 26111481
[TBL] [Abstract][Full Text] [Related]
32. Maize-Produced Ag2 as a Subunit Vaccine for Valley Fever.
Hayden CA; Hung CY; Zhang H; Negron A; Esquerra R; Ostroff G; Abraham A; Lopez AG; Gonzales JE; Howard JA
J Infect Dis; 2019 Jul; 220(4):615-623. PubMed ID: 31184702
[TBL] [Abstract][Full Text] [Related]
33. Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection.
Wüthrich M; Dobson HE; Ledesma Taira C; Okaa UJ; Dos Santos Dias L; Isidoro-Ayza M; Petrovsky N; Klein BS
mBio; 2021 Aug; 12(4):e0201821. PubMed ID: 34399628
[TBL] [Abstract][Full Text] [Related]
34. Novel strategies to enhance vaccine immunity against coccidioidomycosis.
Cole GT; Hung CY; Sanderson SD; Hurtgen BJ; Wüthrich M; Klein BS; Deepe GS; Ostroff GR; Levitz SM
PLoS Pathog; 2013; 9(12):e1003768. PubMed ID: 24367252
[No Abstract] [Full Text] [Related]
35. Both CD4+ and CD8+ T cells can mediate vaccine-induced protection against Coccidioides immitis infection in mice.
Fierer J; Waters C; Walls L
J Infect Dis; 2006 May; 193(9):1323-31. PubMed ID: 16586371
[TBL] [Abstract][Full Text] [Related]
36. A vaccine against coccidioidomycosis is justified and attainable.
Cole GT; Xue JM; Okeke CN; Tarcha EJ; Basrur V; Schaller RA; Herr RA; Yu JJ; Hung CY
Med Mycol; 2004 Jun; 42(3):189-216. PubMed ID: 15283234
[TBL] [Abstract][Full Text] [Related]
37. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice.
Wüthrich M; Gern B; Hung CY; Ersland K; Rocco N; Pick-Jacobs J; Galles K; Filutowicz H; Warner T; Evans M; Cole G; Klein B
J Clin Invest; 2011 Feb; 121(2):554-68. PubMed ID: 21206087
[TBL] [Abstract][Full Text] [Related]
38. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.
Lin L; Ibrahim AS; Xu X; Farber JM; Avanesian V; Baquir B; Fu Y; French SW; Edwards JE; Spellberg B
PLoS Pathog; 2009 Dec; 5(12):e1000703. PubMed ID: 20041174
[TBL] [Abstract][Full Text] [Related]
39. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
[TBL] [Abstract][Full Text] [Related]
40. Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.
Sanderson SD; Thoman ML; Kis K; Virts EL; Herrera EB; Widmann S; Sepulveda H; Phillips JA
PLoS One; 2012; 7(7):e40303. PubMed ID: 22792270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
